Your browser doesn't support javascript.
loading
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study.
Jackson, Callum; Stewart, Iain D; Plekhanova, Tatiana; Cunningham, Peter S; Hazel, Andrew L; Al-Sheklly, Bashar; Aul, Raminder; Bolton, Charlotte E; Chalder, Trudie; Chalmers, James D; Chaudhuri, Nazia; Docherty, Annemarie B; Donaldson, Gavin; Edwardson, Charlotte L; Elneima, Omer; Greening, Neil J; Hanley, Neil A; Harris, Victoria C; Harrison, Ewen M; Ho, Ling-Pei; Houchen-Wolloff, Linzy; Howard, Luke S; Jolley, Caroline J; Jones, Mark G; Leavy, Olivia C; Lewis, Keir E; Lone, Nazir I; Marks, Michael; McAuley, Hamish J C; McNarry, Melitta A; Patel, Brijesh V; Piper-Hanley, Karen; Poinasamy, Krisnah; Raman, Betty; Richardson, Matthew; Rivera-Ortega, Pilar; Rowland-Jones, Sarah L; Rowlands, Alex V; Saunders, Ruth M; Scott, Janet T; Sereno, Marco; Shah, Ajay M; Shikotra, Aarti; Singapuri, Amisha; Stanel, Stefan C; Thorpe, Mathew; Wootton, Daniel G; Yates, Thomas; Gisli Jenkins, R; Singh, Sally J.
Afiliação
  • Jackson C; Department of Mathematics, University of Manchester, Manchester, UK.
  • Stewart ID; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart & Lung Institute, Imperial College London, London, UK.
  • Plekhanova T; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Cunningham PS; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Hazel AL; Department of Mathematics, University of Manchester, Manchester, UK.
  • Al-Sheklly B; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
  • Aul R; St Georges University Hospitals NHS Foundation Trust, London, UK.
  • Bolton CE; Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK; NIHR Nottingham BRC respiratory theme, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
  • Chalder T; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; Persistent Physical Symptoms Research and Treatment Unit, South London and Maudsley NHS Trust, London, UK.
  • Chalmers JD; University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
  • Chaudhuri N; Ulster University, Newtownabbey, UK.
  • Docherty AB; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Donaldson G; National Heart & Lung Institute, Imperial College London, London, UK.
  • Edwardson CL; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Elneima O; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Greening NJ; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Hanley NA; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
  • Harris VC; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Harrison EM; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Ho LP; MRC Human Immunology Unit, University of Oxford, Oxford, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK.
  • Houchen-Wolloff L; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; Department of Respiratory Sciences, University of Leicester, Leicester, UK; Therapy Department, University Hospitals of Leicester, NHS Trust, Leicester, UK.
  • Howard LS; Imperial College Healthcare NHS Trust, London, UK; Imperial College London, London, UK.
  • Jolley CJ; Faculty of Life Sciences & Medicine, King's College Hospital NHS Foundation Trust, London, UK; Kings College London, London, UK.
  • Jones MG; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospitals Southampton, Southampton, UK.
  • Leavy OC; Department of Population Health Sciences, University of Leicester, Leicester, UK.
  • Lewis KE; Hywel Dda University Health Board, Wales, UK; University of Swansea, Wales, UK; Respiratory Innovation Wales, Wales, UK.
  • Lone NI; The Usher Institute, University of Edinburgh, Edinburgh, UK; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
  • Marks M; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, University College London Hospital, London, UK; Division of Infection and Immunity, University College London, London, UK.
  • McAuley HJC; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • McNarry MA; Department of Sport and Exercise Sciences, Swansea University, Swansea, UK.
  • Patel BV; Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, UK; Royal Brompton and Harefield Clinical Group, Guy's andSt Thomas' NHS Foundation Trust, London, UK.
  • Piper-Hanley K; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Poinasamy K; Asthma + Lung UK, London, UK.
  • Raman B; Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Richardson M; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Rivera-Ortega P; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
  • Rowland-Jones SL; Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Rowlands AV; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Saunders RM; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Scott JT; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
  • Sereno M; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Shah AM; Faculty of Life Sciences & Medicine, King's College Hospital NHS Foundation Trust, London, UK; Kings College London, London, UK.
  • Shikotra A; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Singapuri A; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Stanel SC; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
  • Thorpe M; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Wootton DG; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Yates T; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Gisli Jenkins R; National Heart & Lung Institute, Imperial College London, London, UK.
  • Singh SJ; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Lancet Respir Med ; 11(8): 673-684, 2023 08.
Article em En | MEDLINE | ID: mdl-37072018
BACKGROUND: Sleep disturbance is common following hospital admission both for COVID-19 and other causes. The clinical associations of this for recovery after hospital admission are poorly understood despite sleep disturbance contributing to morbidity in other scenarios. We aimed to investigate the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and to assess whether this was associated with dyspnoea. METHODS: CircCOVID was a prospective multicentre cohort substudy designed to investigate the effects of circadian disruption and sleep disturbance on recovery after COVID-19 in a cohort of participants aged 18 years or older, admitted to hospital for COVID-19 in the UK, and discharged between March, 2020, and October, 2021. Participants were recruited from the Post-hospitalisation COVID-19 study (PHOSP-COVID). Follow-up data were collected at two timepoints: an early time point 2-7 months after hospital discharge and a later time point 10-14 months after hospital discharge. Sleep quality was assessed subjectively using the Pittsburgh Sleep Quality Index questionnaire and a numerical rating scale. Sleep quality was also assessed with an accelerometer worn on the wrist (actigraphy) for 14 days. Participants were also clinically phenotyped, including assessment of symptoms (ie, anxiety [Generalised Anxiety Disorder 7-item scale questionnaire], muscle function [SARC-F questionnaire], dyspnoea [Dyspnoea-12 questionnaire] and measurement of lung function), at the early timepoint after discharge. Actigraphy results were also compared to a matched UK Biobank cohort (non-hospitalised individuals and recently hospitalised individuals). Multivariable linear regression was used to define associations of sleep disturbance with the primary outcome of breathlessness and the other clinical symptoms. PHOSP-COVID is registered on the ISRCTN Registry (ISRCTN10980107). FINDINGS: 2320 of 2468 participants in the PHOSP-COVID study attended an early timepoint research visit a median of 5 months (IQR 4-6) following discharge from 83 hospitals in the UK. Data for sleep quality were assessed by subjective measures (the Pittsburgh Sleep Quality Index questionnaire and the numerical rating scale) for 638 participants at the early time point. Sleep quality was also assessed using device-based measures (actigraphy) a median of 7 months (IQR 5-8 months) after discharge from hospital for 729 participants. After discharge from hospital, the majority (396 [62%] of 638) of participants who had been admitted to hospital for COVID-19 reported poor sleep quality in response to the Pittsburgh Sleep Quality Index questionnaire. A comparable proportion (338 [53%] of 638) of participants felt their sleep quality had deteriorated following discharge after COVID-19 admission, as assessed by the numerical rating scale. Device-based measurements were compared to an age-matched, sex-matched, BMI-matched, and time from discharge-matched UK Biobank cohort who had recently been admitted to hospital. Compared to the recently hospitalised matched UK Biobank cohort, participants in our study slept on average 65 min (95% CI 59 to 71) longer, had a lower sleep regularity index (-19%; 95% CI -20 to -16), and a lower sleep efficiency (3·83 percentage points; 95% CI 3·40 to 4·26). Similar results were obtained when comparisons were made with the non-hospitalised UK Biobank cohort. Overall sleep quality (unadjusted effect estimate 3·94; 95% CI 2·78 to 5·10), deterioration in sleep quality following hospital admission (3·00; 1·82 to 4·28), and sleep regularity (4·38; 2·10 to 6·65) were associated with higher dyspnoea scores. Poor sleep quality, deterioration in sleep quality, and sleep regularity were also associated with impaired lung function, as assessed by forced vital capacity. Depending on the sleep metric, anxiety mediated 18-39% of the effect of sleep disturbance on dyspnoea, while muscle weakness mediated 27-41% of this effect. INTERPRETATION: Sleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition. FUNDING: UK Research and Innovation, National Institute for Health Research, and Engineering and Physical Sciences Research Council.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos do Sono-Vigília / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Lancet Respir Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos do Sono-Vigília / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Lancet Respir Med Ano de publicação: 2023 Tipo de documento: Article